+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032- Product Image
Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032- Product Image
Sale

Meningococcal Vaccines Market by Vaccine Type, Age Group, Formulation, Distribution Channel, End User, Indication - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4857895
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Meningococcal Vaccines Market is projected to reach USD 7.16 Billion in 2026. It is expected to continue growing at a CAGR of 11.02%, reaching USD 13.74 Billion by 2032.

The meningococcal vaccines landscape is anchored by the public health priority of preventing invasive meningococcal disease, a fast-progressing infection caused by Neisseria meningitidis that can lead to meningitis, septicemia, long-term disability, and death. According to the World Health Organization, serogroups A, B, C, W, X, and Y account for most disease globally, making broad serogroup coverage central to meningococcal immunization strategy.

Demand is shaped by national immunization programs, outbreak response, travel requirements, adolescent vaccination, military and university policies, and protection for high-risk patients, including people with complement deficiencies, asplenia, or immunosuppression. Conjugate MenACWY vaccines, MenB vaccines, and emerging pentavalent approaches are driving a landscape defined by clinical evidence, regulatory scrutiny, procurement reliability, cold-chain performance, and measurable population-level impact.

Transformative Shifts Reshaping the Vaccine Landscape

The market is shifting from reactive outbreak control toward preventive, lifecycle-based immunization. High-income countries continue to rely on adolescent MenACWY programs and targeted MenB use, while countries in the African meningitis belt have demonstrated the value of mass vaccination and routine immunization after MenA conjugate vaccine deployment, a WHO-recognized intervention associated with major reductions in serogroup A epidemics.

Product strategy is also evolving. Vaccine developers are investing in broader serogroup coverage, simplified schedules, thermostability improvements, and evidence packages that support national immunization technical advisory group recommendations. At the same time, procurement agencies increasingly evaluate not only price per dose but also supply continuity, cold-chain performance, real-world effectiveness, safety monitoring, and compatibility with existing infant, adolescent, travel, and high-risk immunization visits.

Cumulative Impact of Artificial Intelligence on Meningococcal Vaccines

Artificial intelligence is becoming a cumulative accelerator across meningococcal vaccine discovery, surveillance, manufacturing, and market access. In research, AI-enabled antigen screening, protein-structure modeling, and bioinformatics can help prioritize candidates for serogroups with variable epidemiology, including serogroup B and X. In pharmacovigilance and epidemiology, machine learning supports faster signal detection from genomic surveillance, laboratory reports, adverse event databases, and outbreak intelligence systems.

Commercially, AI improves demand planning, inventory allocation, tender preparation, cold-chain risk management, and scenario modeling for outbreak response. Its greatest value is not replacing clinical validation or public health judgment, but compressing decision cycles while maintaining regulatory-grade evidence, explainability, data privacy, cybersecurity, and human oversight in meningococcal vaccine programs.

Key Regional Insights Across Global Meningococcal Vaccine Demand

Asia-Pacific combines large birth cohorts with uneven meningococcal epidemiology, expanding vaccine manufacturing capacity, and differing levels of program maturity. Australia has established adolescent and risk-based meningococcal vaccination policies, Japan and South Korea maintain strong regulatory and surveillance infrastructure, China is expanding domestic vaccine capability and public immunization capacity, and India remains a major vaccine manufacturing and procurement hub with growing attention to adolescent, institutional, and travel health protection.

North America is characterized by mature recommendations, strong public and private reimbursement channels, and defined adolescent vaccination pathways, especially in the United States and Canada. Europe remains policy-driven and heterogeneous, with European regulatory coordination and national immunization technical advisory groups shaping schedules for MenACWY and MenB vaccination. Latin America shows selective public program adoption and outbreak-driven demand in countries such as Brazil and Mexico, where private-sector access also supports uptake. The Middle East is strongly influenced by Hajj and Umrah requirements for quadrivalent meningococcal vaccination, making travel-linked compliance a major demand driver. Africa remains central to global meningitis prevention because the meningitis belt carries the world’s highest epidemic risk, and WHO’s roadmap to defeat meningitis by 2030 continues to support surveillance, outbreak preparedness, and broader vaccine access.

Key Group Insights for Policy, Procurement, and Market Access

ASEAN countries present diverse opportunities because immunization schedules, private-sector uptake, healthcare financing, and disease surveillance capacity vary substantially across member states. Urban private markets, international schools, occupational health, and travel medicine channels support demand, while broader public adoption depends on local disease-burden evidence, affordability, procurement priorities, and cold-chain readiness. The GCC is distinguished by travel-linked vaccination policy, high healthcare investment, and the role of Saudi Arabia’s pilgrimage requirements in sustaining awareness and compliance for MenACWY vaccination.

The European Union offers a robust regulatory, pharmacovigilance, and health technology assessment environment, but meningococcal vaccine adoption remains nationally determined according to epidemiology, budget priorities, and program design. BRICS countries combine large populations, domestic manufacturing ambitions, expanding immunization infrastructure, and rising interest in vaccine security. G7 markets drive clinical evidence standards, premium product uptake, adolescent vaccination policy, and pharmacovigilance expectations, while NATO countries create additional institutional demand through military readiness programs where meningococcal protection is relevant for recruits and personnel living or training in close-quarter settings.

Key Country Insights Shaping Competitive Strategy

In the United States, CDC guidance supports routine MenACWY vaccination for adolescents with a booster dose and shared clinical decision-making for MenB vaccination in young adults, creating a structured demand base across pediatric, college, and high-risk settings. Canada uses provincial and territorial schedules, resulting in differences in access and timing across jurisdictions, while Mexico and Brazil combine public-sector prioritization with private market demand, travel needs, and outbreak response considerations.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent evidence-led markets with varying MenB and MenACWY policies, reflecting national assessments of disease burden, cost-effectiveness, infant and adolescent schedules, and outbreak management. Russia’s demand reflects national epidemiology, procurement priorities, regulatory requirements, and domestic supply considerations. China and India are strategically important because of population scale, immunization infrastructure, and vaccine manufacturing capacity. Japan, Australia, and South Korea offer sophisticated regulatory environments, high healthcare quality expectations, and strong potential for targeted adolescent, travel, university, military, and risk-group vaccination strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate real-world effectiveness, duration of protection, immunogenicity across relevant age groups, herd effects where applicable, and safety in routine and high-risk populations. Market access teams need country-specific dossiers that align with national technical advisory group criteria, health technology assessment expectations, outbreak-response protocols, budget impact requirements, and implementation feasibility.

Vaccine manufacturers should also strengthen supply resilience through diversified antigen sourcing, validated cold-chain controls, robust quality systems, and transparent shortage communication. Strategic growth will favor organizations that pair broader serogroup coverage with affordable procurement models, digital demand forecasting, post-marketing evidence generation, and partnerships with public health agencies, universities, military health systems, travel medicine networks, and outbreak surveillance programs.

Research Methodology and Evidence Base

Research methodology is developed using a structured secondary research approach that triangulates information from the World Health Organization, U.S. Centers for Disease Control and Prevention, national immunization schedules, regulatory agencies, peer-reviewed literature, public health surveillance databases, health technology assessment publications, and public procurement references. Emphasis is placed on verified epidemiology, vaccine policy, approved indications, serogroup coverage, safety monitoring, and documented public health practices.

The analysis compares regional demand drivers, policy adoption, product coverage, access barriers, procurement models, outbreak response practices, and innovation signals. Insights are validated for consistency across credible public sources and presented without unsupported market-size, market-share, or market-forecast claims.

Conclusion: Strategic Outlook for Meningococcal Vaccines

The meningococcal vaccines landscape is moving toward broader protection, smarter surveillance, and more policy-specific access strategies. While disease incidence can be low in many countries, the rapid severity of invasive meningococcal disease keeps vaccination a high-value public health intervention, especially for adolescents, infants in selected programs, travelers, military populations, university students, outbreak settings, and immunocompromised individuals.

Winning strategies will depend on clinical differentiation, reliable supply, affordability, regulatory readiness, and the ability to translate epidemiological evidence into policy action. Stakeholders that combine scientific credibility with regional execution, transparent safety evidence, and resilient procurement support are best positioned to strengthen sustainable access to meningococcal vaccination.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Meningococcal Vaccines Market, by Vaccine Type
7.1. Conjugate
7.2. Polysaccharide
7.3. Protein Subunit
8. Meningococcal Vaccines Market, by Age Group
8.1. Adolescent
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Meningococcal Vaccines Market, by Formulation
9.1. Multi Dose
9.2. Single Dose
10. Meningococcal Vaccines Market, by Distribution Channel
10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy
11. Meningococcal Vaccines Market, by End User
11.1. Clinics
11.2. Hospitals
11.3. Research Institutes
11.4. Vaccination Centers
12. Meningococcal Vaccines Market, by Indication
12.1. Outbreak Response
12.2. Routine Prophylactic
12.3. Traveler Immunization
13. Asia-Pacific Meningococcal Vaccines Market
14. North America Meningococcal Vaccines Market
15. Latin America Meningococcal Vaccines Market
16. Europe Meningococcal Vaccines Market
17. Middle East Meningococcal Vaccines Market
18. Africa Meningococcal Vaccines Market
19. ASEAN Meningococcal Vaccines Market
20. GCC Meningococcal Vaccines Market
21. European Union Meningococcal Vaccines Market
22. BRICS Meningococcal Vaccines Market
23. G7 Meningococcal Vaccines Market
24. NATO Meningococcal Vaccines Market
25. United States Meningococcal Vaccines Market
26. China Meningococcal Vaccines Market
27. Germany Meningococcal Vaccines Market
28. United Kingdom Meningococcal Vaccines Market
29. India Meningococcal Vaccines Market
30. Canada Meningococcal Vaccines Market
31. France Meningococcal Vaccines Market
32. Mexico Meningococcal Vaccines Market
33. Brazil Meningococcal Vaccines Market
34. Australia Meningococcal Vaccines Market
35. Japan Meningococcal Vaccines Market
36. South Korea Meningococcal Vaccines Market
37. Italy Meningococcal Vaccines Market
38. Russia Meningococcal Vaccines Market
39. Spain Meningococcal Vaccines Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Astellas Pharma Inc.
41.2. AstraZeneca PLC
41.3. Bharat Biotech Ltd.
41.4. Bio-Med Private Ltd
41.5. Biological E. Limited
41.6. Chongqing Zhifei Biological Products Co., Ltd.
41.7. GlaxoSmithKline PLC
41.8. Incepta Pharmaceuticals Ltd.
41.9. Merck & Co., Inc.
41.10. Novartis AG
41.11. Pfizer Inc.
41.12. PT Bio Farma
41.13. Sanofi S.A.
41.14. Serum Institute of India Pvt. Ltd.
41.15. Taj Pharmaceuticals Limited
41.16. Walvax Biotechnology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL POLYSACCHARIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL POLYSACCHARIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL POLYSACCHARIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ADOLESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ADOLESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ADOLESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MULTI DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MULTI DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MULTI DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL OUTBREAK RESPONSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ROUTINE PROPHYLACTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TRAVELER IMMUNIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 94. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 95. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 96. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. EUROPE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 103. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 108. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 109. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 110. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 113. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 115. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 116. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 117. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. ASEAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 120. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 122. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 123. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 124. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. GCC MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 134. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 136. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 137. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 138. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. BRICS MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 141. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 143. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 145. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 146. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. G7 MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 150. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 151. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 152. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. NATO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 162. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 163. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 164. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 165. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 166. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 171. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 172. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 173. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 174. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 178. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 184. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 185. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 186. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 187. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 190. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 192. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 193. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 194. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 197. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 198. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 199. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 201. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 204. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 206. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 207. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 208. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 209. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 211. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 213. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 214. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 215. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 218. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 219. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 220. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 221. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 222. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 225. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 226. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 227. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 228. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 229. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 232. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 234. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 235. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 236. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 241. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 242. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 243. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 246. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 247. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 248. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 249. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 250. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 251. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 253. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 255. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
TABLE 256. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 257. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. SPAIN MENINGOCOCCAL VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Meningococcal Vaccines market report include:
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bharat Biotech Ltd.
  • Bio-Med Private Ltd
  • Biological E. Limited
  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PT Bio Farma
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Taj Pharmaceuticals Limited
  • Walvax Biotechnology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.16 Billion
Forecasted Market Value ( USD ) by 2032 $ 13.74 Billion
Compound Annual Growth Rate11.0%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Meningococcal Vaccines - Global Strategic Business Report - Product Image

Meningococcal Vaccines - Global Strategic Business Report

  • Report
  • 142 Pages
  • Global
From
Meningococcal Vaccines Market Size, Share & Trends Analysis Report by Type, Brand, Serotype, Age Group, Sales Channel, Region, and Segment Forecasts, 2026-2033 - Product Image

Meningococcal Vaccines Market Size, Share & Trends Analysis Report by Type, Brand, Serotype, Age Group, Sales Channel, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2026-2034 - Product Image

Meningococcal Vaccines Market Report by Vaccine Type, Composition, Vaccine Serotype, Distribution Channel, End User, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Meningococcal Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Meningococcal Vaccine Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 87 Pages
  • Global
From
Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Meningococcal Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 186 Pages
  • Global
From

About the Meningococcal Vaccine Market

The Meningococcal Vaccine is a type of vaccine used to protect against meningococcal disease, a serious and potentially fatal infection caused by the bacterium Neisseria meningitidis. It is recommended for adolescents and young adults, as well as for those at increased risk of infection, such as travelers to certain countries and those with certain medical conditions. The vaccine is available in both conjugate and polysaccharide forms, and is typically administered in two or three doses. The Meningococcal Vaccine market is part of the larger Infectious Diseases Drugs market, which includes a range of treatments for various infectious diseases. The Meningococcal Vaccine market is expected to grow in the coming years, driven by increasing awareness of the disease and the availability of new vaccines. Some companies in the Meningococcal Vaccine market include GlaxoSmithKline, Merck, Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.